Posts Tagged cancer

UR Medicine’s Wilmot Cancer Institute will be among the first sites in the world to offer CAR T-cell therapy —a new type of immunotherapy approved this week by the FDA—to adults with aggressive lymphoma. The engineered gene therapy has been described as a revolutionary “living drug” and one of the most powerful cancer treatments to emerge in recent years.

Researchers have identified a protein that is required for cell death after undergoing chemotherapy—at least, it appears, in male mice.

Patients with advanced cancer who suffer cardiac arrest in a hospital have a survival rate of less than 10 percent—half the rate of patients without cancer, according to a nationwide study led by the Medical Center.

A new $3 million grant to the Wilmot Cancer Institute allows oncologists to evaluate whether adding vitamin D to standard therapy will help cancer patients live longer.

Researchers from the Center for RNA Biology have identified a new way to potentially slow the fast-growing cells that characterize all types of cancer.

Exercise or psychological therapy work better than medications to reduce cancer-related fatigue and should be recommended first to patients, according to a Wilmot Cancer Institute–led study published in JAMA Oncology.

The largest study to date of memory and cognition problems related to chemotherapy shows that women with breast cancer report substantial issues lasting as long as six months after treatment.

Researchers at the University’s Wilmot Cancer Institute and Roswell Park in Buffalo have discovered a possible new tool for predicting whether prostate cancer will reoccur following surgery based on the expression patterns of four genes.

A Medical Center study explains how the benefits of radiation can be hijacked by the treatment’s tendency to dampen the body’s immune response, and suggests that adding immunotherapy to radiotherapy improves treatment.

University researchers hope to improve the odds of surviving acute myeloid leukemia by loading a promising compound into nanoparticles that will target the inner recesses of bone marrow where leukemia stem cells lurk.